News

Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 ...

Bristol Myers posts better-than-expected second quarter results on strength of top sellers

Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most ...
StockStory.org on MSN6h

Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) announced in Q2 CY2025, but sales were flat year on year at $12.27 ...

Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors

This was the stock's fifth consecutive day of losses.

2BMY : Bristol-Myers Squibb Unusual Options Activity For July 31

Out of all of the special options we uncovered, 26 are puts, for a total amount of $1,771,839, and 16 are calls, for a total amount of $839,064. Taking into account the Volume and Open Interest on ...
TipRanks on MSN4h

Bristol-Myers Squibb’s KarXT Study: A New Hope for Bipolar-I Disorder?

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Bristol Myers Squibb and Bain Capital Form New Immunology Company

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...